NEW YORK (TheStreet) -- Johnson & Johnson (JNJ) is buying Alios Biopharma, a privately held developer of antiviral drugs, for $1.75 billion in cash. J&J's deal announcement this morning highlights Alios' experimental vaccine for respiratory syncytial virus, or RSV, a serious respiratory disease affecting infants and small children.
William Hait, global head of R&D at J&J's Janssen subsidiary, said:
We are excited that this acquisition will enable us to explore treatment options for a number of viral infections, including RSV, the last of the major pediatric diseases with no available preventive therapy. AL-8176 complements our existing early stage portfolio for RSV which aims to prevent and treat this disease, the leading cause of acute lower respiratory infection in children under the age of five.
For investors (or people like me who write about investing), it's always interesting to speculate about the motivations behind significant takeovers, including consideration of companies that may have been passed over.
J&J is not going to tell anyone publicly if it looked at other targets before deciding to buy Alios, but conceivably Novavax (NVAX) could have been on the target list. Novavax is developing an RSV vaccine, among other drugs.
J&J did not buy Novavax.
Outside of RSV, Alios' pipeline includes hepatitis C drugs. If Alios sounds familiar, you probably remember Vertex Pharmaceuticals (VRTX) licensed one of Alios' hepatitis C "nucs" -- ALS-2200. That partnership fizzled when Vertex gave up on hepatitis C. Earlier this month, Alios presented some preclinical data on another Hep C nuc -- AL-335 -- which is wholly owned. Given J&J's commitment to Hep C, it seems likely the Alios acquisition was also motivated by the desire to own another Hep C asset.